Abstract
Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN. Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor ZVAD-fmk almost completely abrogated apoptosis. Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bax protein expression, while Bcl-2 and Bcl-XL protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- BA:
-
bongkrekic acid
- CD95-L:
-
CD95 ligand
- DiOC6(3):
-
3,3′-dihexyloxacarbocyanide iodide
- Doxo:
-
Doxorubicin
- ECL:
-
enhanced chemiluminescence
- FACS:
-
fluorescence-activated cell-sorting
- ICE:
-
interleukin 1β-converting enzyme
- ΔΨm:
-
mitochondrial transmembrane potential
- PARP:
-
poly(ADP-ribose) polymerase
- Z-VAD.fmk:
-
benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone
References
Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD and Dörken B. . 1996 J. Clin. Invest. 96: 2651–2659.
Berthold F. . 1990 Overview: Biology of Neuroblastoma. C Pochedly (ed.).. Boca Raton, Florida: CRC Press. pp. 1–30.
Bissonette RP, Echeverri F, Mahboudi A and Green DR. . 1992 Nature 359: 552–556.
Dong J, Naito M and Tsuruo T. . 1997 Oncogene 15: 639–647.
Eischen CM, Kottke TJ, Martins LM, Basi GS, Tun JS, Earnshaw WC, Leibson PJ and Kaufmann SH. . 1997 Blood 90: 935–943.
Faris N, Kokot K, Latinis S, Kasibhatla DR, Green GA, Koretzky and Nel A. . 1998 J. Immunol. 160: 134–144.
Fisher DE. . 1994 Cell 78: 539–542.
Friesen C, Herr I, Krammer PH and Debatin KM. . 1996 Nat. Med. 2: 574–577.
Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM. . 1997a Cancer Res. 57: 3823–3829.
Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME and Debatin KM. . 1997b Cancer Res. 57: 4956–4964.
Fulda S, Los M, Friesen C and Debatin KM. . 1998a Int. J. Cancer 76: 105–114.
Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME and Debatin KM. . 1998b Cell Death Differ. in press.
Henriksson M and Lüscher B. . 1996 Adv. Cancer Res., 68 109–182.
Hermeking H and Eick D. . 1994 Science 265: 2091–2093.
Herr I, Boehler T, Wilhelm D, Angel P and Debatin KM. . 1997 EMBO J. 16: 6200–6208.
Hueber AO, Zörnig M, Lyon D, Suda T, Nagata S and Evan GI. . 1997 Science 278: 1305–1309.
Janicke RU, Lee FH and Porter AG. . 1994 Mol. Cell. Biol. 14: 5661–5670.
Kischkel FC, Hellbrandt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME. . 1995 EMBO J. 14: 5579–5588.
Klefstrom J, Vastrik I, Saksela E, Valle J, Eilers M and Alitalo K. . 1994 EMBO J. 13: 5442–5450.
Klefstrom J, Arighi E, Littlewood T, Jaattela M, Saksela S, Evan GI and Alitalo K. . 1997 EMBO J. 16: 7382–7392.
Kroemer G. . 1997a Nat. Med. 3: 614–620.
Kroemer G, Zamzami N and Susin SA. . 1997b Immunol. Today 18: 44–51.
Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droege W, Krammer PH, Fiers W and Schulze-Osthoff K. . 1995 Nature 375: 81–83.
Lutz W, Stöhr M, Schürmann J, Wenzel A, Löhr A and Schwab M. . 1996 Oncogene 13: 803–812.
Lutz W, Fulda S, Jeremias I, Debatin KM and Schwab M. . 1998 Oncogene 17: 339–346.
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and Peter ME. . 1997 EMBO J. 16: 2794–2804.
Miyashita T and Reed JC. . 1995 Cell 80: 293–299.
Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME and Dixit VM. . 1996 Cell 85: 817–827.
Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR. . 1997 J. Clin. Invest. 99: 403–413.
Nagata S. . 1997 Cell 88: 355–365.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C. . 1991 J. Immunol. Methods 139: 271–279.
Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M and Saijo N. . 1991 Br. J. Cancer 63: 237–241.
Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H and Krammer PH. . 1992 J. Biol. Chem. 267: 10709–10715.
Packham G, Porter CW and Cleveland JL. . 1996 Oncogene 13: 461–469.
Pastorino JG, Chen ST, Tafani M, Snyder JW and Farber JL. . 1998 J. Biol. Chem. 273: 7770–7775.
Peter ME, Kischkel FC, Hellbrandt S, Chinnaiyan AM, Krammer PH and Dixit VM. . 1996 Cell Death Differ. 3: 161–170.
Scaffidi C, Fulda S, Li F, Friesen C, Srinivasan A, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME. . 1998 EMBO J. 17: 1675–1687.
Scaffidi C, Medema JP, Krammer PH and Peter ME. . 1997 J. Biol. Chem. 272: 26953–26958.
Schwab M, Corvi R and Amler L. . 1995 The Neuroscientist 1: 277–285.
Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R and Schwab M. . 1990 Cancer Res. 50: 4411–4416.
Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, Fassy F, Reed JC and Kroemer G. . 1997 J. Exp. Med. 186: 25–37.
Trauth BC, Klas C, Peter AMJ, Matz S, Möller P, Falk W, Debatin KM and Krammer PH. . 1989 Science 245: 301–305.
Villunger A, Egle A, Kos M, Hartmann B, Geley S, Kofler R and Greil R. . 1997 Cancer Res. 57: 3331–3334.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM. . 1997 EMBO J. 16: 12985–12995.
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ. . 1997 J. Cell Biol. 139: 1281–1292.
Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV and Mak TW. . 1998 Science 279: 1954–1958.
Yu K, Ravera CP, Chen YNP and McMahon G. . 1997 Cell Growth Differ. 8: 731–742.
Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M and Kroemer G. . 1996 J. Exp. Med. 183: 1533–1542.
Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU and Möröy T. . 1995a Oncogene 10: 2397–2401.
Zörnig M, Busch G, Beneke R, Gulbins E, Lang F, Ma A, Korsmeyer S and Möröy T. . 1995b Oncogene 11: 2165–2174.
Acknowledgements
This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium für Forschung and Technologie, Bonn, the Tumor Center Heidelberg/Mannheim, The Deutsche Leukämieforschungshilfe (to K-MD), the Dr Mildred Scheel Stiftung and the Fördergemeinschaft Kinderkrebs-Neuroblastom-Forschung e.V. (to MS).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fulda, S., Lutz, W., Schwab, M. et al. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18, 1479–1486 (1999). https://doi.org/10.1038/sj.onc.1202435
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202435
Keywords
This article is cited by
-
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma
Scientific Reports (2020)
-
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma
Journal of Cancer Research and Clinical Oncology (2018)
-
N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics
Cell Death Discovery (2016)
-
MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells
Cellular Oncology (2015)
-
A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma
Targeted Oncology (2015)